Genfit S.A. (GNFT)
- Previous Close
3.4450 - Open
3.4200 - Bid 3.4100 x 100
- Ask 3.5100 x 100
- Day's Range
3.4000 - 3.5586 - 52 Week Range
2.8940 - 4.7500 - Volume
12,606 - Avg. Volume
6,127 - Market Cap (intraday)
172.02M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
www.genfit.comRecent News: GNFT
Performance Overview: GNFT
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GNFT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GNFT
Valuation Measures
Market Cap
168.58M
Enterprise Value
160.43M
Trailing P/E
--
Forward P/E
5.97
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.61
Price/Book (mrq)
2.37
Enterprise Value/Revenue
5.62
Enterprise Value/EBITDA
-7.22
Financial Highlights
Profitability and Income Statement
Profit Margin
-83.79%
Return on Assets (ttm)
-9.91%
Return on Equity (ttm)
-35.57%
Revenue (ttm)
34.48M
Net Income Avi to Common (ttm)
-28.89M
Diluted EPS (ttm)
-0.6200
Balance Sheet and Cash Flow
Total Cash (mrq)
77.79M
Total Debt/Equity (mrq)
103.28%
Levered Free Cash Flow (ttm)
-43.59M